CClinicalTrials.gg
Sign In
CompletedNCT07131527Updated Jul 9, 2026

Comparison Between Oral Gabapentin Versus Diclofenac Sodium in Post-operative Analgesia Laparoscopic Cholecystectomy

An interventional study of Gabapentin and Diclofenac Sodium in Cholecystitis, Chronic, sponsored by Sohag University. Completed at 1 site in Egypt. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Sohag University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Study summary

this study amis to compare between perioperative oral Gabapentin versus Diclofenac sodium on postoperative analgesia patients undergoing laparoscopic cholecystectomy

02

Conditions studied

  • Cholecystitis, Chronic
03

In context

Cholecystitis

266 studies on the registry are indexed under Cholecystitis; 46 are open to participants now.

This study's enrollment of 60 is below the median of 86 across 167 interventional studies indexed under Cholecystitis.

Browse Cholecystitis studies →

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Age from 20 to 60 years old. Both sexes. American Society of Anesthesiologists (ASA) physical status I- II. Patients undergoing laparoscopic cholecystectomy.

Exclusion criteria

Exclusion Criteria:

Patients with hypertension. Pregnant women. Obese patients with BMI >35 kg/m2. Alcoholics. Patients With DM Patient refusal

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    group A will receive oral Gabapentin

    Patients included in this group will receive 600 mg of gabapentin 2 h before surgery.

    Drug: Gabapentin

  • Active comparator
    group B will receive diclofenac sodium

    Patients included in this group will receive 100 mg diclofenac sodium 2 h before surgery.

    Drug: Diclofenac Sodium

Interventions

  • DrugGabapentin

    oral Gabapentin will be given 2 hours perioperative as postoperative analgesia patients undergoing laparoscopic cholecystectomy

  • DrugDiclofenac Sodium

    oral diclofenac sodium will be given 2 hours perioperative as postoperative analgesia patients undergoing laparoscopic cholecystectomy

06

What researchers measure

Primary outcomes

  1. the effect of preoperative oral Gabapentin versu Diclofenac sodium in adult patient undergoing laparoscopic cholecystectomy

    postoperative pain by Numerical Rating Scale (0 represents "no pain" while 10 represents "the worst pain)

    Time frame: 8 hours after operation

07

Study locations

1 site
  • Sohag university hospital
    Sohag, Egypt
08

References and documents

Publications

  • Abuahmed M, Rashid R. Day-case laparoscopic cholecystectomy in the management of gallbladder disease: a literature review. Langenbecks Arch Surg. 2024 Sep 28;409(1):292. doi: 10.1007/s00423-024-03479-6. PubMed 39340655 ↗
  • Nestor CC, Ng C, Sepulveda P, Irwin MG. Pharmacological and clinical implications of local anaesthetic mixtures: a narrative review. Anaesthesia. 2022 Mar;77(3):339-350. doi: 10.1111/anae.15641. Epub 2021 Dec 14. PubMed 34904711 ↗
  • LaForge JM, Urso K, Day JM, Bourgeois CW, Ross MM, Ahmadzadeh S, Shekoohi S, Cornett EM, Kaye AM, Kaye AD. Non-steroidal Anti-inflammatory Drugs: Clinical Implications, Renal Impairment Risks, and AKI. Adv Ther. 2023 May;40(5):2082-2096. doi: 10.1007/s12325-023-02481-6. Epub 2023 Mar 22. PubMed 36947330 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07131527
Lead sponsor
Sohag University
Responsible party
Manar Zakria Ismail (Resident , Anesthesia , Surgical Icu , Pain management Faculty of Medicine Sohag university, Sohag University) — Principal investigator
First posted
Aug 20, 2025
Start date
Jul 14, 2025
Primary completion
Jan 20, 2026
Completion
Jan 20, 2026
Last update
Jul 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Cholecystitis→

Other studies from this sponsor

Sohag University

Start the discussion